Article
Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection.
BMC infectious diseases - 26 Aug 2014
Scott Jane, Rosa Kathleen, Fu Min, Cerri Karin, Peeters Monika, Beumont Maria, Zeuzem Stefan, Evon Donna M, Gilles Leen
Abstract excerpt
BACKGROUND: Fatigue is a common symptom of chronic hepatitis C virus (HCV) infection and a frequent side-effect of peginterferon/ribavirin (PR) therapy for HCV. This study evaluated the impact of adding the oral HCV NS3/4A protease inhibitor simeprevir to PR on patient-reported fatigue and health status among patients with chronic HCV genotype 1 infection enrolled in the Phase IIb PILLAR and ASPIRE trials...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.